Compare GCO & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCO | VNDA |
|---|---|---|
| Founded | 1924 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.0M | 361.4M |
| IPO Year | 1994 | 2005 |
| Metric | GCO | VNDA |
|---|---|---|
| Price | $34.08 | $6.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $33.00 | $14.90 |
| AVG Volume (30 Days) | 197.3K | ★ 908.3K |
| Earning Date | 06-03-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 171.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,606,898,000.00 | $216,105,000.00 |
| Revenue This Year | $0.78 | $21.35 |
| Revenue Next Year | $2.12 | $37.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.71 | 8.72 |
| 52 Week Low | $21.23 | $4.14 |
| 52 Week High | $43.60 | $9.91 |
| Indicator | GCO | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 43.32 | 49.72 |
| Support Level | $30.79 | $5.97 |
| Resistance Level | $37.35 | $6.73 |
| Average True Range (ATR) | 2.26 | 0.25 |
| MACD | -0.57 | 0.05 |
| Stochastic Oscillator | 10.19 | 74.63 |
Genesco Inc sells footwear, headwear, sports apparel, and accessories. It has four reportable business segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass. The brands of the company are: Journeys; Journeys Kidz; Little Burgundy; Schuh; Johnston & Murphy; and Genesco Brands Group.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.